Director of Formulation Development
Bristol Myers Squibb
Mary Krause, Ph.D., is Director of Formulation Development in the Sterile Drug Product Development Department of Bristol Myers Squibb in New Brunswick, NJ. In this role, Mary leads a team of scientists to support formulation and process development of biologic drug products. She serves as a drug product development team leader for parenteral products, where she has led drug product teams in developing both monoclonal antibodies and novel protein-based modalities, such as antibody drug conjugates, bispecific antibodies, and fusion proteins. Mary has also served as CMC team leader for both early and late-stage clinical products. Mary is passionate about mentoring women in STEM and serves on the global leadership team for the Bristol Myers Squibb Network of Women (B-NOW).
Prior to joining BMS, Mary earned her B.S. and M.S. degrees in Chemistry from Missouri State University and her Ph.D. in Chemistry from the University of Kansas. Her doctoral work focused on the characterization of a novel metal binding peptide tag and resulting metal complexes, including novel platinum-protein conjugates for use as targeted anti-cancer therapeutics. After her graduate studies, Mary continued this research at the University of Kansas as a PhRMA Foundation Post-Doctoral Fellow in Pharmaceutical Chemistry and as a Scientist at Echogen, Inc. – a startup company that licensed this technology. She is lead author/co-inventor on many patents, publications, conference presentations, and invited lectures. Mary is also a member of the Missouri State University Chemistry Department Advisory Board and of the Board of Directors for the Missouri State University Alumni Association.